ATA3219

About Atara Biotherapeutics

Atara Biotherapeutics is a leader in allogeneic T-cell immunotherapy, focused on developing readily available, off-the-shelf cell therapies. Its landmark achievement is the European Commission approval of EBVALLO™ (tabelecleucel) for EBV+ PTLD, the first allogeneic T-cell therapy ever approved. The company's strategy centers on leveraging its proprietary EBV T-cell platform, which avoids gene editing, to build a pipeline targeting cancer and autoimmune diseases, while navigating the complex transition toward commercialization.

Therapeutic Areas

Other B-cell Non-Hodgkin Lymphoma Drugs